Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 156

1.

Long-Term Follow-Up of the Intergroup Exemestane Study.

Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC.

J Clin Oncol. 2017 May 3:JCO2016705640. doi: 10.1200/JCO.2016.70.5640. [Epub ahead of print]

PMID:
28467729
2.

Candida parapsilosis Protects Premature Intestinal Epithelial Cells from Invasion and Damage by Candida albicans.

Gonia S, Archambault L, Shevik M, Altendahl M, Fellows E, Bliss JM, Wheeler RT, Gale CA.

Front Pediatr. 2017 Mar 22;5:54. doi: 10.3389/fped.2017.00054. eCollection 2017.

3.

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.

Gellert P, Segal CV, Gao Q, López-Knowles E, Martin LA, Dodson A, Li T, Miller CA, Lu C, Mardis ER, Gillman A, Morden J, Graf M, Sidhu K, Evans A, Shere M, Holcombe C, McIntosh SA, Bundred N, Skene A, Maxwell W, Robertson J, Bliss JM, Smith I, Dowsett M; POETIC Trial Management Group and Trialists..

Nat Commun. 2016 Nov 9;7:13294. doi: 10.1038/ncomms13294.

4.

Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation.

Haviland JS, Bentzen SM, Bliss JM, Yarnold JR; START Trial Management Group..

Radiother Oncol. 2016 Dec;121(3):420-423. doi: 10.1016/j.radonc.2016.08.027. Epub 2016 Sep 22.

5.

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC.

J Clin Oncol. 2016 Sep 1;34(25):2961-8. doi: 10.1200/JCO.2016.67.3061. Epub 2016 Jun 6.

PMID:
27269946
6.

Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.

Coombes RC, Kilburn LS, Tubiana-Mathieu N, Olmos T, Van Bochove A, Perez-Lopez FR, Palmieri C, Stebbing J, Bliss JM.

Eur J Cancer. 2016 Jun;60:146-53. doi: 10.1016/j.ejca.2016.03.001. Epub 2016 Apr 26.

PMID:
27125966
7.

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.

Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, Coles C, Goodman A, Bahl A, Churn M, Zotova R, Sydenham M, Griffin CL, Morden JP, Bliss JM; FAST-Forward Trial Management Group..

Radiother Oncol. 2016 Jul;120(1):114-8. doi: 10.1016/j.radonc.2016.02.027. Epub 2016 Apr 1.

8.

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.

López-Knowles E, Gao Q, Cheang MC, Morden J, Parker J, Martin LA, Pinhel I, McNeill F, Hills M, Detre S, Afentakis M, Zabaglo L, Dodson A, Skene A, Holcombe C, Robertson J, Smith I, Bliss JM, Dowsett M; POETIC trialists..

Breast Cancer Res. 2016 Apr 1;18(1):39. doi: 10.1186/s13058-016-0696-2.

9.

Reply to S. Kilickap et al, Y. Karakas et al, and I.A. Voutsadakis.

Morden JP, Eeles RA, Bliss JM.

J Clin Oncol. 2016 Jun 10;34(17):2071-2. doi: 10.1200/JCO.2016.66.7709. Epub 2016 Mar 21. No abstract available.

PMID:
27001582
10.

Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer.

Haviland JS, Hopwood P, Mills J, Sydenham M, Bliss JM, Yarnold JR; START Trialists' Group..

Clin Oncol (R Coll Radiol). 2016 Jun;28(6):345-53. doi: 10.1016/j.clon.2016.01.011. Epub 2016 Feb 8.

11.

Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial.

Hayes AJ, Maynard L, Coombes G, Newton-Bishop J, Timmons M, Cook M, Theaker J, Bliss JM, Thomas JM; UK Melanoma Study Group.; British Association of Plastic, Reconstructive and Aesthetic Surgeons.; Scottish Cancer Therapy Network..

Lancet Oncol. 2016 Feb;17(2):184-92. doi: 10.1016/S1470-2045(15)00482-9. Epub 2016 Jan 12.

12.

Neonatal Candidiasis: New Insights into an Old Problem at a Unique Host-Pathogen Interface.

Arsenault AB, Bliss JM.

Curr Fungal Infect Rep. 2015 Dec 1;9(4):246-252. Epub 2015 Sep 7.

13.

Bone marrow micrometastases in early breast cancer-30-year outcome.

Mansi J, Morden J, Bliss JM, Neville M, Coombes RC.

Br J Cancer. 2016 Feb 2;114(3):243-7. doi: 10.1038/bjc.2015.447. Epub 2016 Jan 14.

14.

Exploring the role and function of trial steering committees: results of an expert panel meeting.

Harman NL, Conroy EJ, Lewis SC, Murray G, Norrie J, Sydes MR, Lane JA, Altman DG, Baigent C, Bliss JM, Campbell MK, Elbourne D, Evans S, Sandercock P, Gamble C.

Trials. 2015 Dec 30;16:597. doi: 10.1186/s13063-015-1125-z.

15.

Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom.

Tsang Y, Ciurlionis L, Kirby AM, Locke I, Venables K, Yarnold JR, Titley J, Bliss J, Coles CE; IMPORT Trial Management Group..

Br J Radiol. 2015;88(1056):20150453. doi: 10.1259/bjr.20150453. Epub 2015 Oct 22.

16.

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.

Eeles RA, Morden JP, Gore M, Mansi J, Glees J, Wenczl M, Williams C, Kitchener H, Osborne R, Guthrie D, Harper P, Bliss JM.

J Clin Oncol. 2015 Dec 10;33(35):4138-44. doi: 10.1200/JCO.2015.60.9719. Epub 2015 Sep 28.

PMID:
26417001
17.

NETosis in Neonates: Evidence of a Reactive Oxygen Species-Independent Pathway in Response to Fungal Challenge.

Byrd AS, O'Brien XM, Laforce-Nesbitt SS, Parisi VE, Hirakawa MP, Bliss JM, Reichner JS.

J Infect Dis. 2016 Feb 15;213(4):634-9. doi: 10.1093/infdis/jiv435. Epub 2015 Sep 2.

18.

Hypofractionated radiotherapy in early breast cancer: Clinical, dosimetric and radio-genomic issues.

Yarnold J, Somaiah N, Bliss JM.

Breast. 2015 Nov;24 Suppl 2:S108-13. doi: 10.1016/j.breast.2015.07.025. Epub 2015 Aug 3. No abstract available.

PMID:
26249121
19.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)., Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R.

Lancet. 2015 Oct 3;386(10001):1341-52. doi: 10.1016/S0140-6736(15)61074-1. Epub 2015 Jul 23.

20.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)., Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R.

Lancet. 2015 Oct 3;386(10001):1353-61. doi: 10.1016/S0140-6736(15)60908-4. Epub 2015 Jul 23. Erratum in: Lancet. 2016 Jan 2;387(10013):30.

Supplemental Content

Loading ...
Support Center